Hyundai Bioscience Co., Ltd. (KOSDAQ:048410)
South Korea
· Delayed Price · Currency is KRW 10,890
+10 (0.09%)
Apr 1, 2025, 3:30 PM KST
Hyundai Bioscience Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 15,050 | 9,481 | 7,852 | 9,241 | 12,511 | Upgrade
|
| Other Revenue | -0 | -0 | - | - | - | Upgrade
|
| Revenue | 15,050 | 9,481 | 7,852 | 9,241 | 12,511 | Upgrade
|
| Revenue Growth (YoY) | 58.73% | 20.76% | -15.04% | -26.14% | -58.41% | Upgrade
|
| Cost of Revenue | 3,258 | 4,490 | 5,140 | 6,012 | 6,104 | Upgrade
|
| Gross Profit | 11,792 | 4,992 | 2,712 | 3,229 | 6,408 | Upgrade
|
| Selling, General & Admin | 7,640 | 7,846 | 6,542 | 6,647 | 6,283 | Upgrade
|
| Research & Development | 3,055 | 6,401 | 16,456 | 4,763 | 1,968 | Upgrade
|
| Other Operating Expenses | 38.4 | 42.25 | 27.37 | 61.28 | 40.98 | Upgrade
|
| Operating Expenses | 11,001 | 14,795 | 29,023 | 12,519 | 10,838 | Upgrade
|
| Operating Income | 790.97 | -9,804 | -26,311 | -9,289 | -4,430 | Upgrade
|
| Interest Expense | -2,313 | -314.57 | -448.65 | -3,003 | -1,130 | Upgrade
|
| Interest & Investment Income | 210.7 | 669.19 | 536.69 | 291.71 | 195.91 | Upgrade
|
| Earnings From Equity Investments | -5,730 | - | 8,834 | 93.91 | 1,542 | Upgrade
|
| Currency Exchange Gain (Loss) | 3.73 | -68.67 | 48.15 | 20.39 | -102.31 | Upgrade
|
| Other Non Operating Income (Expenses) | 94.13 | -335.47 | -182.82 | -404.46 | -1,179 | Upgrade
|
| EBT Excluding Unusual Items | -6,944 | -9,853 | -17,524 | -12,291 | -5,104 | Upgrade
|
| Gain (Loss) on Sale of Investments | 14.05 | 123.67 | 910.99 | - | - | Upgrade
|
| Asset Writedown | - | -4,769 | - | -7,517 | -2,829 | Upgrade
|
| Pretax Income | -6,930 | -14,498 | -16,613 | -19,808 | -7,933 | Upgrade
|
| Income Tax Expense | - | 1.04 | -805.47 | 243.5 | 326.46 | Upgrade
|
| Earnings From Continuing Operations | -6,930 | -14,499 | -15,807 | -20,051 | -8,260 | Upgrade
|
| Net Income | -6,930 | -14,499 | -15,807 | -20,051 | -8,260 | Upgrade
|
| Net Income to Common | -6,930 | -14,499 | -15,807 | -20,051 | -8,260 | Upgrade
|
| Shares Outstanding (Basic) | 40 | 40 | 39 | 37 | 36 | Upgrade
|
| Shares Outstanding (Diluted) | 40 | 40 | 39 | 37 | 36 | Upgrade
|
| Shares Change (YoY) | 0.25% | 0.91% | 6.64% | 2.79% | 3.67% | Upgrade
|
| EPS (Basic) | -174.00 | -365.00 | -401.53 | -543.16 | -229.99 | Upgrade
|
| EPS (Diluted) | -174.00 | -365.00 | -402.00 | -543.16 | -230.00 | Upgrade
|
| Free Cash Flow | 2,087 | -6,548 | -18,087 | -4,285 | -17,702 | Upgrade
|
| Free Cash Flow Per Share | 52.42 | -164.84 | -459.44 | -116.08 | -492.91 | Upgrade
|
| Gross Margin | 78.35% | 52.65% | 34.53% | 34.95% | 51.22% | Upgrade
|
| Operating Margin | 5.26% | -103.40% | -335.10% | -100.52% | -35.41% | Upgrade
|
| Profit Margin | -46.04% | -152.92% | -201.33% | -216.97% | -66.02% | Upgrade
|
| Free Cash Flow Margin | 13.87% | -69.06% | -230.36% | -46.37% | -141.49% | Upgrade
|
| EBITDA | 1,425 | -8,369 | -24,529 | -6,586 | -652.3 | Upgrade
|
| EBITDA Margin | 9.47% | -88.27% | - | -71.27% | -5.21% | Upgrade
|
| D&A For EBITDA | 633.82 | 1,435 | 1,782 | 2,703 | 3,778 | Upgrade
|
| EBIT | 790.97 | -9,804 | -26,311 | -9,289 | -4,430 | Upgrade
|
| EBIT Margin | 5.26% | -103.40% | - | -100.52% | -35.41% | Upgrade
|
| Advertising Expenses | 267.64 | 996.63 | 965.59 | 1,497 | 798.47 | Upgrade
|
Updated Mar 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.